Investors Question JUUL Board Members over Financial Distress in November 2022

Business by 2FIRSTS.ai
Jan.03.2024
Investors Question JUUL Board Members over Financial Distress in November 2022
Investors of JUUL Labs have questioned the financial relief provided to its board members, alleging it benefited insiders, harming other investors.

A group of JUUL Labs investors has raised concerns about a financial relief transaction conducted by JUUL board members Nick Pritzker and Riaz Valani in November 2022, according to The Wall Street Journal. They allege that the deal has benefited insiders while harming the interests of other investors.

 

As a pioneer in the e-cigarette industry, JUUL Labs has shifted from dominating the American market to fighting for survival in a short period of time. After achieving initial success, the company faced regulatory scrutiny due to its marketing practices. Thousands of lawsuits alleging that the company facilitated an "epidemic" of e-cigarette use among minors have notably impacted its financial situation.

 

JUUL is considering bankruptcy since June 2022, after the FDA ordered the removal of its e-cigarettes from the market and obtained a court injunction.

 

In order to avoid bankruptcy, Pritzker and Valani refinanced JUUL's loan deadlines in September 2022 and subsequently loaned funds to cover operational costs during the autumn. Finally, the two directors, along with JUUL's co-founders James Monsees and Adam Bowen, supported a comprehensive legal and investment agreement, which involved equity investment in JUUL.

 

JUUL successfully raised $1.27 billion in funding in October 2023, after engaging with numerous potential investors. This funding includes an additional $45 million investment from Pritzker, Valani, and two co-founders of JUUL, as well as legal entities associated with JUUL and four other investors.

 

Entities associated with Valani and Pritzker now collectively hold nearly half of JUUL's shares, while the majority of other investors have significantly reduced their holdings during the crisis.

 

D1 Capital Partners, an affiliate of hedge fund, along with two other investors, filed a lawsuit against JUUL in October 2023, alleging that Pritzker and Valani "exploited the company's distress to further their own personal interests, thereby harming other stakeholders of JUUL.

 

JUUL plans to raise $330 million in 2024 to maintain its existing product line in the US market and submit new e-cigarette products for federal authorization.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

From Partnership to Acquisition: Why KT&G Is Betting on the Global Nicotine Pouch Market
From Partnership to Acquisition: Why KT&G Is Betting on the Global Nicotine Pouch Market
As global competition in the nicotine pouch market accelerates, Korea’s tobacco major KT&G has moved with a “Partnership + Acquisition” strategy, teaming up with Altria to acquire Nordic pouch maker Another Snus Factory (brand “LOOP”). Why deploy capital now, and why take this route? Drawing on company disclosures, regulatory monitoring and on-site observations from InterTabac Dortmund, 2Firsts analyzes KT&G’s strategic calculus and the signals behind this move.
Nov.05
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Juul Wins UK Court Injunction, Ending Five-Year Legal Battle Against Chinese Vape Infringers
Juul Wins UK Court Injunction, Ending Five-Year Legal Battle Against Chinese Vape Infringers
The UK High Court has granted U.S. e-cigarette manufacturer Juul Labs a permanent injunction against four Chinese companies, bringing an end to a five-year patent and trademark infringement case. The defendants — Greensun Technology, Ouch, Gaish, and Airsmo Tech — failed to respond to any court communications or legal filings.
Oct.30 by 2FIRSTS.ai
Imperial Brands FY25 Results: NGP Net Revenue Up 13.7%, Americas Surges Nearly 70%
Imperial Brands FY25 Results: NGP Net Revenue Up 13.7%, Americas Surges Nearly 70%
Imperial Brands reported FY25 NGP net revenue of £368 million, up 13.7% at constant currency. Growth in the Americas accelerated sharply, with NGP revenue up 69.8%, driven by the expansion of the modern oral brand Zone. Europe delivered 8.8% growth, supported by blu’s double-digit vapour share across key markets. Adjusted NGP operating losses narrowed to £76 million, putting the category closer to breakeven.
Nov.18 by 2FIRSTS.ai
InterTabac 2025 Insights | Caffeine and nicotine-free pouches hit the stage as white-label manufacturing and big players enter, heating up competition
InterTabac 2025 Insights | Caffeine and nicotine-free pouches hit the stage as white-label manufacturing and big players enter, heating up competition
2Firsts discovers at the 2025 InterTabac Exhibition in Dortmund, Germany that nicotine pouches are a top category.
Sep.24 by 2FIRSTS.ai
Euromonitor: RRP Market Reaches $74 Billion, Accounting for 12.7% of Global Nicotine Industry as Five Key Trends Drive Transformation
Euromonitor: RRP Market Reaches $74 Billion, Accounting for 12.7% of Global Nicotine Industry as Five Key Trends Drive Transformation
In 2025, global tobacco leaf production surged, but prices stagnated as climate change intensified farming risks. 2Firsts reports from the ITGA meeting, revealing structural challenges and transition pressures in the industry.
Sep.29